Immunovant, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

Immunovant, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31	2020-03-31
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$413.84M	-$259.34M	-$210.96M	-$156.73M	-$107.43M	-$66.39M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-2.00	$-1.00	$-1.00	–	$-1.22	$-1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-2.00	$-1.00	$-1.00	$-1.43	–	–

Balance Sheet

	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31	2020-03-31
Cash and highly liquid short-term investments the company can access almost immediately.	$714.00M	$635.40M	$376.50M	$493.82M	$400.10M	$100.57M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$776.22M	$666.37M	$405.84M	–	$412.49M	$109.39M
Everything the company owes — debt, unpaid bills, and other obligations.	$68.78M	$48.61M	$43.34M	–	$21.01M	$15.32M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$707.45M	$617.76M	$362.49M	–	$391.48M	$94.07M

Cash Flow Statement

	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31	2020-03-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$375.87M	-$214.23M	-$188.19M	-$106.11M	-$83.33M	-$53.36M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$759000	$360000	$197000	$254000	$210000	$31000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$376.63M	-$214.59M	-$188.39M	-$106.37M	-$83.54M	-$53.39M